Dacomitinib d10

Dacomitinib d10 is a deuterated analog of dacomitinib, a tyrosine kinase inhibitor that is used in the treatment of non-small cell lung cancer. The deuterated form of the drug contains ten deuterium atoms, which are stable isotopes of hydrogen. This modification enhances the metabolic stability and prolongs the half-life of the drug, resulting in increased efficacy and reduced toxicity. Dacomitinib d10 works by inhibiting the activity of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), both of which are implicated in the development and progression of cancer. By blocking the activity of these receptors, dacomitinib d10 prevents cancer cells from growing and dividing, leading to their eventual death. The drug is typically administered orally in the form of tablets, and the recommended dosage varies depending on the patient's age, weight, and overall health status. Common side effects of dacomitinib d10 include diarrhea, rash, fatigue, and nausea. Chemically, dacomitinib d10 has a molecular formula of C24H15D10ClFN5O3 and a molecular weight of 521.04 g/mol. It is a white to off-white powder that is soluble in dimethylsulfoxide and slightly soluble in water. The drug is stable under normal conditions and should be stored in a dry, cool place away from direct sunlight.